19. Pershing LH.; Reilly CA.; Corlett JL.; Crouch DJ.; Effects of vehicule on the uptake and elimination kinetics of capsaicinoids in human skin in vivo. Toxicol. Appl. Pharmacol. 200, 2004,73-81
20. Suresh D.: SrinivassanK.; Tissue distribution and eleimination of capsaicin, piperine and curcumin following oral intake in rats. Indian J. med Res. 2010; 131,682-691
21. Capsaicina 8% parches en dolor neuropático periférico. Informe para la Guía Farmacoterapéutica de Hospitales de Andalucía. 30/06/2011
22. Winter J, Forbes CA, Stemberg J, Lindsay RM. Nerve growth factor (NGF) regulates adult rat cultured dorsal root ganglion neuron response to the excitoxin capsicina .Neuron 1988;1:973-81.
23. Lindsay RM, Harmar AJ, Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature 1989;337:362-4.
24. Nolana M, Simone DA. Wandelschafer Crabb G, Johnson T Hazen E, KennedyWR. Topical capsicin in humans: parallel loss of epidernal nerve fibres and pain sensation. Pain 1999;81:135-45.
25. Szolcsanyi J, Bartho L. Impared defense mechanism to peptic ulcer in the capsaicin-desensitized rat. Advanced in Physiological Sciencies Vol.29, Gastrointestinal Defense Mechanism, Mozsik, Hanninan, Javor (Eds)1981,39-51. Pergamon Press, Oxford-AkademiaiKiado, Budapest
26. Szolcsanyi J. Capsaicin sensitive chemoprotective neural system with dual sensory-afferent function. SzolcsanyiJ, Lembeck F. (Eds) Antidromic Vasodilatation and Neurogenic Inflammation. 1984, 27-56. Akademiai Kiado, Budapest
27. Moznik GY, Vincze A, SzocsanyiJ. Four response of capsaicin sensitive primary afferent neurons to capsaicin and its analogs. Gastric acid secretion, gastric mucosa; damage and protection. J. Gastroenterol. Hepatol. 2001 :16: 193-197
28. Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Baldoni M, Serpico R. Systemic capsaicin for burning mouth syndrome: short-term results of a pilot study. J Oral Pathol Med 2004; 33: 111-4.
29. Garcia CM., GuzmanF., MoraE., Buitrago G., Reyes LE., Gomez A. Capsaicina intravesical: una alternativa en pacientes con vejiga hiperactiva idiopática de difícil manejo. RevistaMed. 2005 13(1) : 70-74
30. Suhr YJ, Lee SS. Capsaicin, a double-edged sword: Toxicity, metabolism and chemoprevent potential. LifeSci 1995;1845-5531.
31. Attuquayeffio V.K, BuckleK .A, Rapid sample preparation ,ethod for HPLC analyses of capsinoids in capsicum fruits andeoleoresins. J.Agric. Food Chem. 35 (1987)777-779
32. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 1997 Sep; 46 Suppl 2:S54-7. Review. PubMed PMID: 9285500.
33. Said G. Diabetic neuropathy–a review. Nat ClinPract Neurol. 2007 Jun;3(6):331-40. Review. PubMed PMID: 17549059.
34. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care 2010; 33(Suppl. 1):S11–S61
35. Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J. 2006;82(964):95-100.
36. Lunn MP, Hughs RA, Wiffen PJ. Duloxitine for treating painfull neuropathy or chronic pain. Cochrane Database Syst Rev 2099; 7:CD007115
37. Chhabra N., Aseri ML., Goyal V., Sankhla S. Capsaicin: A promising therapy-A critical reapprisal. Inter.Jou.Nut: Vol. 2, Issue 1,2012: 8-15
38. Edwars JE, Vincent AM, Cheng HT, Feldman EM. Diabetic Neuropathy: Mechanism to management. Phrmacology& Therapeutics. Vol. 120: Issue 1; 2008; 1-34
39. Revista International Association for the Study of Pain. Published by Elsevier B.V.doi:10.1016./j.pain. 2004.12.010
40. Chad D. Aronin N, Lundstrom R, McKenon P, Moltich M et al. Does capsaicin relieve the pain of diabetic neuropathy ?.Pain 1990 ; 42 :387-388
41. The capsaicin study group. Treatment of painful diabetic neuropathy with topical capsaicin: a multicenter, double-blind, vehicle-controlled study. Arch Intern Med 1991; 151: 2225-2229
42. Scheffler NM, Sheitel PL, Lipton MN. Treatmente of painful diabeteic neuropathy with capsaicin 0.075%. J Am Podiatr Med Assoc 1991; 81 (6): 288-293
43. Tandan R, Lewis G, Badger G, Timo J. Topical capsaicin in painful diabetic neuropathy: effect on sensory function. Diabetes Care 1992 ; 15(1) : 15-18
44. Tandan R, Lewis G, Krusinski P, Badger G, Timothy J. Topical capsaicin in painful diabetic neuropathy:effect on sensory function Diabetes care 1992; 15(1) 8-14
45. The capsaicin study group.Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992: 15: 159-165
46. McQuay H, Tramer M, Nye BA. A systematic review antidepressants in neuropathic pain. Pain 1996 ;68 ;217 227
47. Sarto T, Wiffin PJ. Antideressants for neuropathic pain. Cochrane Database Syst Rev 2005; CD005454
48. McQuay H ,Carrol D, Jadad AR et al. Anticonvulsant drugs for the management of pain A systematic review.BMJ 1995: 311; 1047 1052
49. Wiffen P, Collins S, McQuay H el al. Anticonvulsant drug for acute and chronic pain . Cochrane Database Systrev: 2005; 20 : CD 001133
50. Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painfull neuropathy. Expert Rev Neurother 2006;6:1629 1635
51. Harati Y, Gooch C, Swnson M et al. A intence of the long term effectiveness of tramadol in treatment of the pain of diabetic neuropathy.J Diabets Complications 2000 ;14 ;65 70
52. McCartney CJ, Sinha A, Katz J.A qualitive systemativ review of the role N methyl D aspartate receptor antagonist in preventive analgesia. Anesth Analg 2004;98;1385 1400
53. Winters J, Beaven S. Campbell E. Capsaicin and pain mechanism. Br.J. Anaesth. 1995;75: 157-168
54. Journal of Neurology, Neosurgery & Psichiatry 2003; 74:ii3-ii8 doi:10.1136/jnnp.74. suppl_2_ii3